

Adam T Whaley-Connell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1895224/adam-t-whaley-connell-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

221
papers

8,530
citations

49
h-index

83
g-index

250
ext. papers

9,737
ext. citations

5.1
avg, IF

6.03
L-index

#	Paper	IF	Citations
221	Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance.. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2022 ,	3.2	2
220	Inhibition of sphingomyelinase attenuates diet - Induced increases in aortic stiffness.. <i>Journal of Molecular and Cellular Cardiology</i> , 2022 , 167, 32-39	5.8	0
219	Mineralocorticoid Receptor in Myeloid Cells Mediates Angiotensin II-Induced Vascular Dysfunction in Female Mice. <i>Frontiers in Physiology</i> , 2021 , 12, 588358	4.6	0
218	DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F505-F517	4.3	1
217	Renal resistive index as a novel biomarker for cardiovascular and kidney risk reduction in type II diabetes. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 231-233	2.3	2
216	Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice. <i>Metabolism: Clinical and Experimental</i> , 2020 , 109, 154223	12.7	7
215	Endothelial sodium channel (ENaC) activation contributes to mineralocorticoid receptormediated increases in coronary artery and cardiac fibrosis/stiffness leading to diastolic dysfunction in obesity. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
214	Western diet induces renal artery endothelial stiffening that is dependent on the epithelial Na channel. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, F1220-F1228	4.3	9
213	Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor. <i>Hypertension</i> , 2019 , 73, 849-858	8.5	28
212	Insulin Resistance and the Metabolic Syndrome in Kidney Disease (e.g., the Cardiorenal Metabolic Syndrome) 2019 , 3-13		
211	Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice. <i>Metabolism: Clinical and Experimental</i> , 2019 , 99, 57-66	12.7	26
210	Utility of obesity and metabolic dyslipidemia (a non-insulin based determinate of the metabolic syndrome and insulin resistance) in predicting arterial stiffness. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 1071-1074	2.3	3
209	SAT-LB011 Role of Endothelium Epithelial Sodium Channel in Arterial Stiffness. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
208	Sexual Dimorphism in Obesity-Associated Endothelial ENaC Activity and Stiffening in Mice. <i>Endocrinology</i> , 2019 , 160, 2918-2928	4.8	10
207	Deficiency of IL12p40 (Interleukin 12 p40) Promotes Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 212-223	9.4	26
206	Diabetes and Hypertension: Clinical Update. <i>American Journal of Hypertension</i> , 2018 , 31, 515-521	2.3	9
205	Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition. <i>Advances in Chronic Kidney Disease</i> , 2018 , 25, 158-165	4.7	6

204	Enhanced endothelium epithelial sodium channel signaling prompts left ventricular diastolic dysfunction in obese female mice. <i>Metabolism: Clinical and Experimental</i> , 2018 , 78, 69-79	12.7	28
203	Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. <i>Pharmacology & Therapeutics</i> , 2018 , 191, 1-22	13.9	70
202	Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. <i>Diabetologia</i> , 2018 , 61, 21-28	10.3	268
201	Arterial Stiffness in Hypertension: an Update. <i>Current Hypertension Reports</i> , 2018 , 20, 72	4.7	45
200	The Role of Insulin Resistance in the Cardiorenal Syndrome 2018 , 117-124		
199	Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. <i>Cardiovascular Diabetology</i> , 2017 , 16, 9	8.7	134
198	Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. <i>Kidney International</i> , 2017 , 92, 313-323	9.9	70
197	Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity?. <i>CardioRenal Medicine</i> , 2017 , 8, 41-49	2.8	37
196	Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. <i>Metabolism: Clinical and Experimental</i> , 2017 , 74, 32-40	12.7	36
195	Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. <i>Cardiovascular Diabetology</i> , 2017 , 16, 61	8.7	38
194	Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet. <i>Frontiers in Physiology</i> , 2017 , 8, 456	4.6	29
193	Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	20
192	Blood Pressure-Related Outcomes in a Diabetic Population. <i>Hypertension</i> , 2016 , 68, 34-5	8.5	3
191	Metabolic Control of Blood Pressure Variability in Humans. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 25-6	2.3	2
190	Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice. <i>Hypertension</i> , 2015 , 66, 99-107	8.5	107
189	Obesity and insulin resistance in resistant hypertension: implications for the kidney. <i>Advances in Chronic Kidney Disease</i> , 2015 , 22, 211-7	4.7	33
188	Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension. <i>Advances in Chronic Kidney Disease</i> , 2015 , 22, 185-95	4.7	10
187	Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. <i>Hypertension</i> , 2015 , 65, 531-9	8.5	94

186	BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 2159-69	6.9	37
185	Endothelial Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in Females. <i>Hypertension</i> , 2015 , 66, 1159-1167	8.5	87
184	Hypertension Management in Diabetic Kidney Disease. <i>Diabetes Spectrum</i> , 2015 , 28, 175-80	1.9	16
183	Two-dimensional zymography differentiates gelatinase isoforms in stimulated microglial cells and in brain tissues of acute brain injuries. <i>PLoS ONE</i> , 2015 , 10, e0123852	3.7	6
182	Cardiorenal Metabolic Syndrome and Diabetes in African Americans: Adding to the Risk of Hypertension 2015 , 137-150		
181	Fructose and uric acid: is there a role in endothelial function?. <i>Current Hypertension Reports</i> , 2014 , 16, 434	4.7	34
180	The use and interpretation of troponin in ESRD patients. <i>Seminars in Dialysis</i> , 2014 , 27, 545-7	2.5	3
179	Diabetic kidney disease: a report from an ADA Consensus Conference. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 510-33	7.4	324
178	Diabetic kidney disease: a report from an ADA Consensus Conference. <i>Diabetes Care</i> , 2014 , 37, 2864-83	14.6	539
177	Basic science: Pathophysiology: the cardiorenal metabolic syndrome. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 604-6		19
176	Salt Loading Promotes Kidney Injury via Fibrosis in Young Female Ren2 Rats. <i>CardioRenal Medicine</i> , 2014 , 4, 43-52	2.8	7
175	Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. <i>Endocrinology</i> , 2014 , 155, 2266-76	4.8	40
174	Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. <i>Kidney International</i> , 2014 , 85, 686-92	9.9	51
173	Implications for glucose measures in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. <i>Diabetes</i> , 2014 , 63, 45-7	0.9	6
172	DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. <i>Obesity</i> , 2014 , 22, 2172-9	8	56
171	Chronic Kidney Disease and Cardiovascular Risk. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2014 , 49-61		
170	Obesity and heart failure as a mediator of the cerebrorenal interaction. <i>Contributions To Nephrology</i> , 2013 , 179, 15-23	1.6	7
169	Type 2 diabetes in older people; the importance of blood pressure control. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 233-237	0.9	7

168	Advances in CKD detection and determination of prognosis: executive summary of the National Kidney Foundation-Kidney Early Evaluation Program (KEEP) 2012 annual data report. <i>American Journal of Kidney Diseases</i> , 2013 , 61, S1-3	7.4	12
167	Hypertension and Diabetes Mellitus 2013 , 313-319		
166	Therapy of obese patients with cardiovascular disease. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 200-45.1	9	
165	The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013 , 61, S12-23	7.4	51
164	Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013 , 61, 404-12	7.4	38
163	Association between lack of health insurance and risk of death and ESRD: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013 , 61, S24-32	7.4	39
162	Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 1761-71	12.7	9
161	Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 861-72	12.7	20
160	Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013 , 42, 789-808	5.5	25
159	Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013 , 61, S4-11	7.4	29
158	Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. <i>Molecular and Cellular Endocrinology</i> , 2013 , 378, 53-8	4.4	17
157	Liquid meal composition, postprandial satiety hormones, and perceived appetite and satiety in obese women during acute caloric restriction. <i>European Journal of Endocrinology</i> , 2013 , 168, 593-600	6.5	13
156	Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. <i>Endocrinology</i> , 2013 , 154, 2501-13	4.8	79
155	To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. <i>Pharmacotherapy</i> , 2013 , 33, 496-514	5.8	19
154	No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. <i>Kidney International</i> , 2013 , 84, 989-97	9.9	45
153	DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. <i>CardioRenal Medicine</i> , 2013 , 3, 48-56	2.8	46
152	Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 304, F1105-13	4.3	5
151	Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. <i>Endocrinology</i> , 2013 , 154, 159-71	4.8	39

150	The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2013 , 3, 120-127	2.8	8
149	Enhanced coronary vasoconstriction in western diet-induced obesity is associated with alterations in NHE1, SERCA2a and 3. <i>FASEB Journal</i> , 2013 , 27, lb660	0.9	
148	Associations between access to care and awareness of CKD. <i>American Journal of Kidney Diseases</i> , 2012 , 59, S16-23	7.4	23
147	Access to health care among adults evaluated for CKD: findings from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2012 , 59, S5-15	7.4	35
146	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2011: executive summary. <i>American Journal of Kidney Diseases</i> , 2012 , 59, S1-4	7.4	6
145	Physician utilization, risk-factor control, and CKD progression among participants in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2012 , 59, S24-33	7.4	24
144	Association of physician care with mortality in Kidney Early Evaluation Program (KEEP) participants. <i>American Journal of Kidney Diseases</i> , 2012 , 59, S34-9	7.4	7
143	Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. <i>Regulatory Peptides</i> , 2012 , 176, 36-44		15
142	Awareness of kidney disease and relationship to end-stage renal disease and mortality. <i>American Journal of Medicine</i> , 2012 , 125, 661-9	2.4	38
141	Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). <i>BMC Nephrology</i> , 2012 , 13, 104	2.7	9
140	Hypertension in Chronic Kidney Disease 2012 , 35-50		
139	Predictors of Kidney Disease in Diabetic, Hypertensive Patients 2012 , 107-119		
138	Diabetic Vascular Disease 2012 , 1321-1328		
137	The Role of Insulin Resistance in the Cardiorenal Syndrome 2012 , 137-144		
136	Insulin Resistance and the Autonomic Nervous System 2012 , 307-312		5
135	Oxidative stress in the cardiorenal metabolic syndrome. <i>Current Hypertension Reports</i> , 2012 , 14, 360-5	4.7	45
134	Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H2341-51	5.2	41
133	Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. <i>American Journal of Hypertension</i> , 2012 , 25, 604-11	2.3	29

132	The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4414-21	5.6	7
131	Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. <i>American Journal of Nephrology</i> , 2012 , 35, 90-100	4.6	21
130	Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms. <i>CardioRenal Medicine</i> , 2012 , 2, 225-233	2.8	15
129	Novel role for the incretins in blood pressure regulation. <i>Current Opinion in Nephrology and Hypertension</i> , 2012 , 21, 463-8	3.5	8
128	Comparison of CKD awareness in a screening population using the Modification of Diet in Renal Disease (MDRD) study and CKD Epidemiology Collaboration (CKD-EPI) equations. <i>American Journal of Kidney Diseases</i> , 2011 , 57, S17-23	7.4	25
127	Hypertension in the high-cardiovascular-risk populations. <i>International Journal of Hypertension</i> , 2011 , 2011, 746369	2.4	4
126	Ask the Experts: How can the National Kidney Foundation's Kidney Early Evaluation Program help to prevent/manage kidney disease in diabetic patients?. <i>Diabetes Management</i> , 2011 , 1, 365-368	0	
125	Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 1757-66	12.7	19
124	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011 , 57, S9-16	7.4	98
123	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011 , 57, S24-31	7.4	21
122	Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011 , 57, S4-8	7.4	19
121	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. <i>American Journal of Kidney Diseases</i> , 2011 , 57, S1-3	7.4	7
120	Resistant hypertension in the high-risk metabolic patient. <i>Current Diabetes Reports</i> , 2011 , 11, 41-6	5.6	15
119	Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). <i>Current Diabetes Reports</i> , 2011 , 11, 47-55	5.6	34
118	Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. <i>Endocrinology</i> , 2011 , 152, 659-68	4.8	33
117	Biomarkers in diabetic kidney disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2011 , 8, 121-127		1
116	The Role of Overweight and Obesity in the Cardiorenal Syndrome. <i>CardioRenal Medicine</i> , 2011 , 1, 5-12	2.8	82
115	Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms. <i>CardioRenal Medicine</i> , 2011 , 1, 23-30	2.8	15

114	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2011 , 1, 45-52	2.8	12
113	Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. <i>CardioRenal Medicine</i> , 2011 , 1, 53-66	2.8	9
112	Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome). <i>CardioRenal Medicine</i> , 2011 , 1, 67-74	2.8	12
111	The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. <i>CardioRenal Medicine</i> , 2011 , 1, 102-112	2.8	34
110	The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2011 , 1, 123-130	2.8	10
109	Use of Metformin in Patients with Kidney and Cardiovascular Diseases. <i>CardioRenal Medicine</i> , 2011 , 1, 87-95	2.8	27
108	Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. <i>American Journal of Nephrology</i> , 2011 , 34, 115-25	4.6	36
107	Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. <i>CardioRenal Medicine</i> , 2011 , 1, 193-210	2.8	38
106	Hypertension in Cardiovascular and Kidney Disease. <i>CardioRenal Medicine</i> , 2011 , 1, 183-192	2.8	33
105	A Case for Early Screening for Diabetic Kidney Disease. <i>CardioRenal Medicine</i> , 2011 , 1, 235-242	2.8	3
104	Aldosterone and Risk for Insulin Resistance. <i>Hypertension</i> , 2011 , 58, 998-1000	8.5	11
103	Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 301, H1540-50	5.2	25
102	Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H1484-91	5.2	56
101	Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011 , 301, R885-95	3.2	36
100	Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H181-90	5.2	17
99	The importance of early identification of chronic kidney disease. <i>Missouri Medicine</i> , 2011 , 108, 25-8	0.8	7
98	The role of oxidative stress in the metabolic syndrome. <i>Reviews in Cardiovascular Medicine</i> , 2011 , 12, 21-9	3.9	88
97	Current Therapy Targeting Oxidative Stress: Statin 2011 , 351-366		

96	Effect of Age in RAS Activation and Insulin Signaling in the Pancreatic Tissue of db/db Mice. <i>FASEB Journal</i> , 2011 , 25, 1063-7	0.9	
95	Cytokines in Skeletal Muscle Insulin Resistance 2011 , 369-383		
94	Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. <i>Hypertension</i> , 2010 , 55, 880-8	8.5	97
93	Micro vs. macrovascular reactivity in insulin resistance: the debate reignited. <i>American Journal of Hypertension</i> , 2010 , 23, 458	2.3	
92	Is there a future for direct renin inhibitors?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 653-61	5.9	3
91	Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP). <i>Diabetes Care</i> , 2010 , 33, 2586-91	14.6	27
90	Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F655-61	4.3	34
89	Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. <i>American Journal of Nephrology</i> , 2010 , 31, 262-72	4.6	13
88	Exercise and the metabolic syndrome with weight regain. <i>Journal of Applied Physiology</i> , 2010 , 109, 3-10	3.7	41
87	Should targeting albuminuria be part of a cardiovascular risk reduction paradigm?. <i>Cardiology Clinics</i> , 2010 , 28, 437-45	2.5	
86	Tonsillectomy for the treatment of tonsillitis-induced immunoglobulin A nephropathy. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2010 , 31, 485-8	2.8	4
85	Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. <i>Journal of Molecular Medicine</i> , 2010 , 88, 993-1001	5.5	253
84	The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. <i>Current Diabetes Reports</i> , 2010 , 10, 37-42	5.6	28
83	Cytokine abnormalities in the etiology of the cardiometabolic syndrome. <i>Current Hypertension Reports</i> , 2010 , 12, 93-8	4.7	38
82	Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010 , 55, S23-33	7.4	194
81	Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010 , 55, S4-S14	7.4	17
80	Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 385-9	12.7	21
79	Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. <i>Progress in Cardiovascular Diseases</i> , 2010 , 52, 401-9	8.5	113

78	Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 51-8	2.3	25
77	The effects of resistance training on metabolic health with weight regain. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 64-72	2.3	7
76	Contribution of oxidative stress to pulmonary arterial hypertension. <i>World Journal of Cardiology</i> , 2010 , 2, 316-24	2.1	76
75	Effect of ethnicity on the progression of diabetic kidney disease independent of glycemic control. <i>American Journal of Nephrology</i> , 2009 , 30, 261-7	4.6	3
74	Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. <i>American Journal of Nephrology</i> , 2009 , 30, 354-60	4.6	49
73	Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. <i>Endocrinology</i> , 2009 , 150, 2561-8	4.8	83
72	Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 296, F1013-22	4.3	36
71	Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 296, H1184-92	5.2	63
70	Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H1128-39	5.2	22
69	Glycemic control and cardiovascular disease in a high-risk chronic kidney disease population. <i>Therapy: Open Access in Clinical Medicine</i> , 2009 , 6, 507-513		1
68	Low aerobic capacity and high-fat diet contribute to oxidative stress and IRS-1 degradation in the kidney. <i>American Journal of Nephrology</i> , 2009 , 30, 112-9	4.6	17
67	Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. <i>Hypertension</i> , 2009 , 53, 158-65	8.5	32
66	Hypertension and insulin resistance. <i>Hypertension</i> , 2009 , 54, 462-4	8.5	33
65	Nebivolol in obese and non-obese hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 309-15	15.3	20
64	Renin-Angiotensin-Aldosterone System Inhibition and Improvement in Glucose Tolerance. <i>Journal of Clinical Hypertension</i> , 2009 , 11, S40-S47	2.3	0
63	Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). <i>American Journal of Kidney Diseases</i> , 2009 , 53, S11-21	14	74
62	Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?. <i>Current Hypertension Reports</i> , 2009 , 11, 375-81	4.7	1
61	Inhibition of nitric oxide synthase evokes central sympatho-excitation in healthy humans. <i>Journal of Physiology</i> , 2009 , 587, 4977-86	3.9	43

60	Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. <i>Translational Research</i> , 2009 , 153, 102-13	11	26
59	Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. <i>American Journal of Pathology</i> , 2009 , 174, 1329-37	5.8	48
58	Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. <i>Annals of Internal Medicine</i> , 2009 , 150, 776-83	8	253
57	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <i>Vascular Health and Risk Management</i> , 2009 , 5, 129-40	4.4	23
56	Mineralocorticoid Receptor (MR) Inhibition Attenuates High Salt-Aldosterone Induced Increases in Vascular Renin-Angiotensin-Aldosterone System (RAAS) and Oxidative Stress. <i>FASEB Journal</i> , 2009 , 23, 626.18	0.9	
55	Direct renin inhibition with Aliskiren lowers blood pressure and improves renal dysfunction in Ren2 rats. <i>FASEB Journal</i> , 2009 , 23, 606.13	0.9	
54	Rosuvastatin Attenuates Pulmonary Arterial Hypertension in the Transgenic (mREN2)27 (Ren2) Rat. <i>FASEB Journal</i> , 2009 , 23, 770.4	0.9	
53	Mineralocorticoid Receptor (MR) Antagonism Attenuates Glomerular Filtration Barrier Remodeling in the Transgenic Ren2 Rat. <i>FASEB Journal</i> , 2009 , 23, 803.16	0.9	
52	Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S21-9	7.4	42
51	CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S13-20	7.4	141
50	CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S38-45	7.4	107
49	Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S56-68	7.4	48
48	Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S46-55	7.4	72
47	CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2008 , 52, 382-3	7.4	34
46	Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. <i>Journal of the Cardiometabolic Syndrome</i> , 2008 , 3, 234-43		47
45	Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 318-27	4.9	1
44	Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. <i>Journal of Hepatology</i> , 2008 , 49, 417-28	13.4	77
43	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>American Heart Journal</i> , 2008 , 156, 277-83	4.9	116

42	Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008 , 294, R673-80	3.2	162
41	Outcomes of carotid revascularization in patients with chronic kidney disease. <i>Advances in Chronic Kidney Disease</i> , 2008 , 15, 347-54	4.7	2
40	Redox control of renal function and hypertension. <i>Antioxidants and Redox Signaling</i> , 2008 , 10, 2047-89	8.4	127
39	Obesity, insulin resistance, and nocturnal systolic blood pressure. <i>Hypertension</i> , 2008 , 51, 620-1	8.5	8
38	Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 295, E110-6	6	85
37	Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 295, E103-9	6	50
36	Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H2659-68	5.2	61
35	Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. <i>Hypertension</i> , 2008 , 51, 474-80	8.5	83
34	Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. <i>Endocrinology</i> , 2008 , 149, 5643-53	4.8	65
33	Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. <i>American Journal of Nephrology</i> , 2008 , 28, 67-75	4.6	41
32	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <i>Vascular Health and Risk Management</i> , 2008 , 129	4.4	3
31	Antihypertensive medications and their effects on lipid metabolism. <i>Current Diabetes Reports</i> , 2008 , 8, 214-20	5.6	12
30	The cardiometabolic syndrome and chronic kidney disease. <i>Current Cardiovascular Risk Reports</i> , 2008 , 2, 95-100	0.9	
29	Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2007 , 1, 107-12	3.4	3
28	Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2007 , 1, 27-35	3.4	17
27	Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H2009-23	5.2	214
26	Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. <i>Current Diabetes Reports</i> , 2007 , 7, 208-17	5.6	12
25	Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. <i>Endocrinology</i> , 2007 , 148, 2181-8	4.8	65

24	Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, F861-7	4.3	25
23	Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 293, E355-63 ⁶		79
22	Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. <i>Endocrinology</i> , 2007 , 148, 3773-80	4.8	88
21	Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. <i>American Journal of Nephrology</i> , 2007 , 27, 15-23	4.6	57
20	Obesity and chronic kidney disease: therapeutic implications. <i>Therapy: Open Access in Clinical Medicine</i> , 2007 , 4, 585-595		1
19	NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. <i>Hypertension</i> , 2007 , 50, 384-91	8.5	94
18	Chronic kidney disease and cardiovascular risk. <i>Journal of the American Society of Hypertension</i> , 2007 , 1, 178-84		22
17	Overexpression of the Tissue Renin-Angiotensin System Causes Pulmonary Hypertension (PH) in TG(mRen2)27 Rat. <i>FASEB Journal</i> , 2007 , 21, A1252	0.9	
16	Obesity and insulin resistance as risk factors for chronic kidney disease. <i>Journal of the Cardiometabolic Syndrome</i> , 2006 , 1, 209-14; quiz 215-6		23
15	Cardiometabolic syndrome and chronic kidney disease: what is the link?. <i>Journal of the Cardiometabolic Syndrome</i> , 2006 , 1, 58-65		32
14	Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. <i>American Journal of Nephrology</i> , 2006 , 26, 579-89	4.6	35
13	Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, F1308-14	4.3	94
12	Diabetic hypertension. <i>Heart Failure Clinics</i> , 2006 , 2, 25-36	3.3	4
11	Role of angiotensin II in diabetic cardiovascular and renal disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006 , 13, 135-140		6
10	Hypertension and Cardiovascular Disease 2006 , 499-513		2
9	Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. <i>American Journal of Nephrology</i> , 2005 , 25, 553-69	4.6	68
8	Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2209-21	4	13
7	Hypertension and the cardiometabolic syndrome. <i>Journal of Clinical Hypertension</i> , 2005 , 7, 471-6	2.3	50

6	Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 63-75	5.5	20
5	The cardiometabolic syndrome as a cardiovascular risk factor. <i>American Journal of the Medical Sciences</i> , 2005 , 330, 311-8	2.2	61
4	The key role of insulin resistance in the cardiometabolic syndrome. <i>American Journal of the Medical Sciences</i> , 2005 , 330, 290-4	2.2	48
3	Rates of continuous ambulatory peritoneal dialysis-associated peritonitis at the University of Missouri. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2005 , 21, 72-5		9
2	Recommendations for Special Populations 2004 , 14, 368-381		7
1	Meal Frequency Differentially Alters Postprandial Triacylglycerol and Insulin Concentrations in Obese Women. <i>Obesity</i> ,	8	2